1. A disubstituted 3,4-diamine-3-cyclobutene-1,2-dione compound corresponding to general formula (I) below, or one of the pharmaceutically acceptable salts or solvates thereof:
in which:
R1 represents a hydrogen atom or a methyl,
R2 represents a ring comprising five atoms, selected from the group consisting of structures (1), (2), (3) and (4) below:
in which R5, R7a, X and X\u2032 have the meaning given hereinafter,
R3 represents an aromatic or heteroaromatic ring selected from the group consisting of the rings corresponding to formulae (a) to (o) below:
in which R7, R7a, Y and Z have the meaning given hereinafter, it being specified that the rings (a) to (o) can optionally bear several R7 groups, which are identical or different, the total number of such R7 groups being at most equal to the number of substitutable atoms of the ring;
R4 represents an aromatic or heteroaromatic ring selected from the group consisting of the rings corresponding to formulae (p) to (z) and (aa) to (ak) below:
in which R7, R8, R9, R10, R11, R12, R13, R14 and R15 have the meaning given hereinafter,
R5 represents a hydrogen atom, a fluorine atom, an alkyl radical having from 1 to 5 carbon atoms or a fluoroalkyl or perfluoroalkyl radical comprising from 1 to 5 carbon atoms,
R6 represents a hydrogen atom, a \u2014COOtBu radical or a \u2014COOBn radical,
R7 represents a halogen, or an \u2014R16, \u2014CF3, \u2014COR16, \u2014OR16, \u2014NR16R17, \u2014NO2, \u2014CN, \u2014SO2NR16, \u2014SO2R16R17, \u2014NR16COR17, \u2014CONR16R17, \u2014NR16CO2R17 or \u2014CO2R16 radical,
R7a represents a hydrogen atom or an alkyl radical having from 1 to 5 carbon atoms,
R8 represents a hydrogen atom, a halogen atom, an \u2014OH radical, or an \u2014SH, \u2014CONHOR16, \u2014CONR16OH, \u2014NR16R17, \u2014SO3H, \u2014OCOR16, \u2014NHSO2R16, \u2014SO2NR16R17, \u2014NHCOR16, \u2014CONR16R17, \u2014NR16CO2R17, \u2014NHSO2NR16R17, CO2R16, pyrrolyl, imidazolyl, triazolyl or tetrazolyl radical,
R9, R10, R11 and R12 are identical or different and are independently selected from the group consisting of a hydrogen, a halogen atom and an alkyl, alkoxy, \u2014CF3, OCF3, \u2014OH, \u2014NO2, \u2014CN, \u2014SO2R16, \u2014SO2NR16R17, \u2014NR16COR17, \u2014NR16CO2R17, \u2014CONR16R17, \u2014COR16 and \u2014CO2R16 radical,
or alternatively, when two of the R9, R10, R11 and R12 radicals are in the ortho position on an aromatic or heteroaromatic ring selected from the group consisting of the rings corresponding to formulae (p) to (z) and (aa) to (ak) above, then they can together form, with the bond which links them together, an aryl, heteroaryl, cycloalkyl or heterocycloalkyl ring,
R13 and R14 are identical or different and are independently selected from the group consisting of a hydrogen atom, a halogen atom, and an alkyl, \u2014CF3, \u2014OCF3, \u2014OH, \u2014SH, \u2014CN, \u2014SO2R16, \u2014SO2NR16R17, \u2014NHSO2NR16R17, \u2014NR16R17, \u2014NR16CONR16R17, \u2014NR16COR17, \u2014NR16CO2R17, \u2014CONR16R17, \u2014COR16 and \u2014CO2R16 radical,
R15 represents a hydrogen atom or an \u2014OH, \u2014SO2R16, \u2014COR16, \u2014CO2R16, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkyl, cycloalkyl or cycloalkylalkyl radical,
R16 and R17 are identical or different and are independently selected from the group consisting of a hydrogen atom, one of the following radicals: aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkyl, fluoroalkyl having from 1 to 5 carbon atoms, cycloalkyl or cycloalkylalkyl, and a \u2014CH2COOR18 group in which R18 represents an alkyl radical having from 1 to 5 carbon atoms,
or alternatively, when R16 and R17 are borne by the same nitrogen atom, they form a heterocycle having between 3 and 7 ring members and optionally comprising one or two heteroatoms chosen from oxygen, sulfur and nitrogen in addition to the common nitrogen atom by which they are borne, it being possible for said heterocycle to be substituted with an alkyl group having from 1 to 5 carbon atoms or a \u2014COOR18 group in which R18 represents an alkyl radical having from 1 to 5 carbon atoms;
X and X\u2032, which are identical or different, represent an oxygen atom, a sulfur atom, or a nitrogen atom substituted with an R6 radical,
Y represents an oxygen atom, a sulfur atom, or a nitrogen atom substituted with an R15 radical, and
Z represents a carbon or nitrogen atom.
2. The compound as claimed in claim 1, wherein, in the abovementioned formula (I):
R1 represents a hydrogen atom,
R2 represents a five-membered ring selected from the group consisting of structures (1), (2) and (3) below:
in which R5, R7a, X and X\u2032 have the meaning given hereinafter,
R3 represents an aromatic or heteroaromatic ring selected from the group consisting of the rings corresponding to formulae (a), (b) and (d) below:
in which R7, R7a, Y and Z have the meaning given hereinafter, it being specified that the rings (a), (b) and (d) can optionally bear several R7 groups, which are identical or different, the total number of such R7 groups being at most equal to the number of substitutable atoms of the ring;
R4 represents an aromatic or heteroaromatic ring selected from the group consisting of the rings corresponding to formulae (p), (q), (t), (z), (ad), (ag) and (ah) below:
in which R8, R9, R10, R11, R12, R13 and R15 have the meaning given hereinafter,
R5 represents a hydrogen atom, a fluorine atom, an alkyl radical having from 1 to 5 carbon atoms or a fluoroalkyl or perfluoroalkyl radical comprising from 1 to 5 carbon atoms,
R6 represents a hydrogen atom, a \u2014COOtBu radical or a \u2014COOBn radical,
R7 represents a halogen, or an R16, \u2014CF3, \u2014COR16, \u2014OR16, \u2014NR16R17, \u2014NO2, \u2014CN, \u2014SO2R16, \u2014SO2NR16R17, \u2014NR16COR17, \u2014CONR16R17, \u2014NR16CO2R17 or \u2014CO2R16 radical,
R7a represents a hydrogen or an alkyl radical having from 1 to 5 carbon atoms,
R8 represents a hydrogen atom, or
an \u2014OH, \u2014SH, \u2014CONHOR16, \u2014CONR160H, \u2014NR16R17, \u2014SO3H, \u2014OCOR16, \u2014NHSO2R16, \u2014SO2NR16R17, \u2014NHCOR16, \u2014CONR16R17, \u2014NR16CO2R17, \u2014NHSO2NR16R17, \u2014CO2R16, pyrrolyl, imidazolyl, triazolyl or tetrazolyl radical,
R9, R10, R11 and R12 are identical or different and are independently selected from the group consisting of a hydrogen atom, a halogen atom and an alkyl, alkoxy, \u2014CF3, \u2014OCF3, \u2014OH, \u2014NO2, \u2014CN, \u2014SO2R16, \u2014SO2NR16R17, \u2014NR16COR17, \u2014NR16CO2R17, \u2014CONR16R17, \u2014COR16 and \u2014CO2R16 radical,
or alternatively, when two of the R9, R10, R11 and R12 radicals are in the ortho position on an aromatic or heteroaromatic ring selected from the group consisting of the rings corresponding to formulae (p), (q), (t), (z), (ad), (ag) and (ah) above, then they can together form, with the bond which links them together, an aryl, heteroaryl, cycloalkyl or heterocycloalkyl ring,
R13 is selected from the group consisting of a hydrogen atom, a halogen atom, and an alkyl, \u2014CF3, \u2014OCF3, \u2014OH, \u2014SH, \u2014CN, \u2014SO2R16, \u2014SO2NR16R17, \u2014NHSO2NR16R17, \u2014NR16R 17, \u2014NR16CONR16R17, \u2014NR16COR17, \u2014NR16CO2R17, \u2014CONR16R17, \u2014COR16 and \u2014CO2R16 radical,
R15 represents a hydrogen atom or an \u2014OH, \u2014SO2R16, \u2014COR16, \u2014CO2R16, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkyl, cycloalkyl or cycloalkylalkyl radical,
R16 and R17 are identical or different and are independently selected from the group consisting of a hydrogen atom, one of the following radicals: aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkyl, fluoroalkyl having from 1 to 5 carbon atoms, cycloalkyl or cycloalkylalkyl, and a \u2014CH2COOR18 group in which R18 represents an alkyl radical having from 1 to 5 carbon atoms,
or alternatively, when R16 and R17 are borne by the same nitrogen atom, they form a heterocycle having between 3 and 7 ring members and optionally comprising one or two heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen in addition to the common nitrogen atom by which they are borne, it being possible for said heterocycle to be substituted with an alkyl group having from 1 to 5 carbon atoms or a \u2014COOR18 group in which R18 represents an alkyl radical having from 1 to 5 carbon atoms;
X and X\u2032, which are identical or different, represent an oxygen atom, a sulfur atom, or a nitrogen atom substituted with an R6 radical,
Y represents an oxygen atom, a sulfur atom, or a nitrogen atom substituted with an R15 radical, and
Z represents a carbon or nitrogen atom.
3. The compound as claimed in claim 1 wherein in the abovementioned formula (I):
R1 represents a hydrogen atom,
R2 represents a ring comprising five atoms, having the structure (I) below:
in which R5 and X have the meaning given hereinafter,
R3 represents a heteroaromatic ring corresponding to formula (d) below:
in which R7, Y and Z have the meaning given hereinafter, it being specified that the ring (d) can optionally bear several R7 groups, which are identical or different, the total number of such R7 groups being at most equal to the number of substitutable atoms of the ring;
R4 represents an aromatic ring corresponding to formula (t) below:
in which R8, R9, R10, R11 and R12 have the meaning given hereinafter,
R5 represents a hydrogen atom, a fluorine atom, an alkyl radical having from 1 to 5 carbon atoms or a fluoroalkyl or perfluoroalkyl radical comprising from 1 to 5 carbon atoms,
R6 represents a hydrogen atom, a \u2014COOtBu radical or a \u2014COOBn radical,
R7 represents a halogen atom, or an R16, \u2014CF3, \u2014COR16, \u2014OR16, \u2014NR16R17, \u2014NO2, \u2014CN, \u2014SO2R16, \u2014SO2NR16R17, \u2014NR16COR17, \u2014CONR16R17, \u2014NR16CO2R17 or \u2014CO2R16 radical,
R8 represents a hydrogen atom, or an \u2014OH, \u2014SH, \u2014CONHOR16, \u2014CONR160H, \u2014NR16R17, SO3H, \u2014OCOR16, \u2014NHSO2R16, \u2014SO2NR16R17, \u2014NHCOR16, \u2014CONR16R17, \u2014NR16CO2R17, \u2014NHSO2NR16R17, \u2014CO2R16, pyrrolyl, imidazolyl, triazolyl or tetrazolyl radical,
R9, R10, R11 and R12 are identical or different and are independently selected from the group consisting of a hydrogen atom, a halogen atom and an alkyl, alkoxy, CF3, \u2014OCF3, \u2014OH, \u2014NO2, \u2014CN, \u2014SO2R16, \u2014SO2NR16R17, \u2014NR16COR17, \u2014NR16CO2R17, \u2014CONR16R17, \u2014COR16 and \u2014CO2R16 radical,
or alternatively, when two of the R9, R10, R11 and R12 radicals are in the ortho position on the aromatic ring (t), they can together form, with the bond which links them together, an aryl, heteroaryl, cycloalkyl or heterocycloalkyl ring,
R15 represents a hydrogen atom or an \u2014OH, \u2014SO2R16, \u2014COR16, \u2014CO2R16, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkyl, cycloalkyl or cycloalkylalkyl radical,
R16 and R17 are identical or different and are independently selected from the group consisting of a hydrogen atom, one of the following radicals: aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkyl, fluoroalkyl having from 1 to 5 carbon atoms, cycloalkyl or cycloalkylalkyl, and a \u2014CH2COOR18 group in which R18 represents an alkyl radical having from 1 to 5 carbon atoms,
or alternatively, when R16 and R17 are borne by the same nitrogen atom, they form a heterocycle having between 3 and 7 ring members and optionally comprising one or two heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen in addition to the common nitrogen atom by which they are borne, it being possible for said heterocycle to be substituted with an alkyl group having from 1 to 5 carbon atoms and a \u2014COOR18 group in which R18 represents an alkyl radical having from 1 to 5 carbon atoms;
X represents an oxygen atom, a sulfur atom, or a nitrogen atom substituted with an R6 radical,
Y represents an oxygen atom, a sulfur atom, or a nitrogen atom substituted with an R15 radical, and
Z represents a carbon or nitrogen atom.
4. A pharmaceutical composition comprising an effective amount of a compound, or of a pharmaceutically acceptable salt of said compound, as claimed in claim 1, in combination with a pharmaceutically acceptable solvent or support.
5. The compound as claimed in claim 1 or a pharmaceutical composition comprising the compound for use as a medicament.
6. The compound as claimed in claim 1 or a pharmaceutical composition comprising the compound for use in the treatment of \u03b1-chemokine-mediated diseases.
7. The compound or the pharmaceutical composition as claimed in claim 6, for use in the treatment of diseases selected from the group comprising neutrophilic dermatosis, psoriasis, atopic dermatitis, acne, rosacea, asthma, chronic obstructive pulmonary diseases, respiratory diseases in adults, arthritis, inflammatory bowel diseases, Crohn’s disease, transplant rejection, cystic fibrosis and skin cancers.
8. The compound or the pharmaceutical composition as claimed in claim 6, for use in the treatment of skin diseases selected from the group consisting of neutrophilic dermatosis, psoriasis, atopic dermatitis, acne and rosacea.
9. The compound as claimed in claim 1, selected from the group consisting of:
1-2-hydroxy-N,N-dimethyl-3-(2-{(5-methylfuran-2-yl)-(2-methyltetrahydrofuran-2-yl)methylamino}-3,4-dioxocyclobut-1-enylamino)benzamide;
2-2-hydroxy-N,N-dimethyl-3-(2-{(5-methylfuran-2-yl)-(tetrahydrothiophen-2-yl)methylamino}-3,4-dioxocyclobut-1-enylamino)benzamide;
3-methyl (S)-1-2-fluoro-3-(2-{(5-methylfuran-2-yl)-(tetrahydrothiophen-2-yl)methylamino}-3,4-dioxocyclobut-1-enylamino)benzoylpyrrolidine-2-carboxylate;
4-isopropyl (S)-1-2-fluoro-3-(2-{(5-methylfuran-2-yl)-(tetrahydrothiophen-2-yl)methylamino}-3,4-dioxocyclobut-1-enylamino)benzoylpyrrolidine-2-carboxylate;
5-ethyl (S)-1-2-fluoro-3-(2-{(5-methylfuran-2-yl)-(tetrahydrothiophen-2-yl)methylamino}-3,4-dioxocyclobut-1-enylamino)benzoylpyrrolidine-2-carboxylate;
6-methyl (R)-1-2-hydroxy-3-(2-{(5-methylfuran-2-yl)-(tetrahydrothiophen-2-yl)methylamino}-3,4-dioxocyclobut-1-enylamino)benzoylpyrrolidine-2-carboxylate;
7-methyl (S)-1-2-hydroxy-3-(2-{(5-methylfuran-2-yl)-(tetrahydrothiophen-2-yl)methylamino}-3,4-dioxocyclobut-1-enylamino)benzoylpyrrolidine-2-carboxylate;
8-2-hydroxy-N-methyl-3-(2-{(S)-(5-methylfuran-2-yl)tetrahydrothiophen-2-ylmethylamino}-3,4-dioxocyclobut-1-enylamino)-N-(2,2,2-trifluoroethyl)benzamide;
9-methyl {2-hydroxy-3-(2-{(5-methylfuran-2-yl)-(tetrahydrothiophen-2-yl)methylamino}-3,4-dioxocyclobut-1-enylamino)benzoylmethylamino}acetate;
10-6-chloro-2-hydroxy-N,N-dimethyl-3-(2-{(5-methylfuran-2-yl)-(tetrahydrothiophen-2-yl)methylamino}-3,4-dioxocyclobut-1-enylamino)benzenesulfonamide;
11-2-hydroxy-N,N-dimethyl-3-(2-{(R)-(5-methylfuran-2-yl)tetrahydro-furan-2-ylmethylamino}-3,4-dioxocyclobut-1-enylamino)benzamide;
12-2-hydroxy-N,N-dimethyl-3-(2-{(S)-(5-methylfuran-2-yl)tetrahydrofuran-2-ylmethylamino}-3,4-dioxocyclobut-1-enylamino)benzamide;
13-3-(3,4-dioxo-2-{phenyl(tetrahydrofuran-2-yl)methylamino}cyclobut-1-enylamino)-2-hydroxy-N,N-dimethylbenzamide;
14-3-(2-{((R)-2,2-dimethyl-1,3dioxolan-4-yl)-(5-methylfuran-2-yl)methylamino}-3,4-dioxocyclobut-1-enylamino)-2-hydroxy-N,N-dimethylbenzamide;
15methyl (S)-1-2-fluoro-3-(2-{(5-methylfuran-2-yl)-(tetrahydrothiophen-2-yl)methylamino}-3,4-dioxocyclobut-1-enylamino)benzoylpyrrolidine-2-carboxylate;
163-(2-hydroxypyridin-3-ylamino)-4-{(5-methylfuran-2-yl)-(tetrahydrothiophen-2-yl)methylamino}cyclobut-3-ene-1,2-dione;
173-{(5-methylfuran-2-yl)-(tetrahydrothiophen-2-yl)-methyl-amino}-4-(1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)cyclobut-3-ene-1,2-dione;
18(\u2212)-2-hydroxy-N-methyl-3-(2-{(S)-(5-methylfuran-2-yl)-(tetrahydrothiophen-2-yl)methylamino}-3,4-dioxocyclobut-1-enylamino)-N-(2,2,2-trifluoroethyl)benzamide;
19methyl (\u2212)-{2-hydroxy-3-(2-{(S)-(5-methylfuran-2-yl)-(tetrahydrothiophen-2-yl)methylamino}-3,4-dioxocyclobut-1-enylamino)benzoylmethylamino}acetate;
20methyl (\u2212)-1-2-hydroxy-3-(2-{((S)-5-methylfuran-2-yl)-(tetrahydrothiophen-2-yl)methylamino}-3,4-dioxocyclobut-1-enylamino)benzoylpyrrolidine-2-(R)-carboxylate;
21(\u2212)-6-chloro-2-hydroxy-N,N-dimethyl-3-(2-{((S)-5-methylfuran-2-yl)-(tetrahydrothiophen-2-yl)methylamino}-3,4-dioxocyclobut-1-enylamino)benzamide; and
22(\u2212)-3-4-chloro-2-hydroxy-3-(4-methylpiperazine-1-sulfonyl)phenylamino-4-{5-methylfuran-2-yl)-(tetrahydrothiophen-2-yl)methylamino}cyclobut-3-ene-1,2-dione.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A computer-implemented method of configuring a process in a computer system, comprising:
displaying a process identifying user interface display with identifying user input mechanisms that receive process identifying user inputs that identify a process to be configured, the identifying user input mechanisms including an entity identifier input mechanism that receives an entity identification user input identifying a first entity corresponding to the process;
displaying a process flow definition user interface display with process flow user input mechanisms that receive process flow user inputs that define a flow for the process, corresponding to the first entity; and
after receiving the process identifying user inputs and the process flow user inputs, storing the process for access by users of the computer system.
2. The computer-implemented method of 1 wherein the computer system comprises a business system, the process comprises a business process in the computer system and the first entity comprises a first business entity and wherein displaying the process flow user input mechanisms comprises:
displaying a stages user input mechanism that receives a stages user input identifying stages of the business process.
3. The computer-implemented method of claim 2 wherein displaying the process flow user input mechanisms comprises:
displaying a steps user input mechanism receiving a steps user input identifying steps to be completed at each stage of the business process.
4. The computer-implemented method of claim 3 wherein displaying the process flow user input mechanisms comprises:
displaying a required user input mechanism receiving a required user input identifying selected steps as being required before advancing to a subsequent stage in the business process.
5. The computer-implemented method of claim 4 wherein displaying the process flow user input mechanisms comprises:
displaying a fields user input mechanism receiving a fields user input identifying fields of the first entity affected by each step in each stage.
6. The computer-implemented method of claim 5 wherein displaying the process flow user input mechanisms comprises:
displaying an entity selector user input mechanism on the process flow definition user interface display; and
receiving entity selection user inputs that identify subsequent entities that correspond to subsequent stages in the business process, so the business process spans a plurality of different entities.
7. The computer-implemented method of claim 6 wherein displaying the process flow user input mechanisms comprises:
displaying a role assignment user input mechanism that receives a role assignment user input indicative of roles in the business system that have access to the business process.
8. The computer-implemented method of claim 7 wherein displaying the process flow user input mechanisms comprises:
displaying a stage category user input mechanism that receives a stage category user input assigning a stage category to each stage in the business process.
9. A computer-implemented method of performing a process in a computer system, comprising:
displaying a process user interface display, for a selected process, that includes a stages display showing an ordered set of stages that are to be performed, in order, to perform the selected process, and a steps display showing steps to be completed for a selected stage, along with steps user input mechanisms that receive steps user inputs to complete the steps;
displaying an entity display on the process user interface display that identifies an entity corresponding to the selected stage; and
displaying a location indicator, indicative of a location on the stages display that the selected process is in.
10. The computer-implemented method of claim 9 wherein the computer system comprises a business system, wherein the process comprises a business process within the business system and wherein the entity comprises a business entity in the business system
11. The computer-implemented method of claim 10 wherein displaying a process user interface display comprises:
displaying an advance user input mechanism that receives an advance user input to advance to a subsequent stage from the selected stage; and
in response to the advance user input, determining whether all required steps for the selected stage have been completed.
12. The computer-implemented method of claim 11 and further comprising:
if all of the required steps for the selected stage have not been completed, displaying an indication that the process cannot advance to the subsequent stage until all the required steps have been completed.
13. The computer-implemented method of claim 12 and further comprising:
if all the required steps for the selected stage have been completed, marking the selected stage as being complete on the stages display; and
advancing the location indicator to the subsequent stage on the stages display.
14. The computer-implemented method of claim 13 and further comprising:
displaying a steps display showing steps to be completed for the subsequent stage, along with steps user input mechanisms that receive steps user inputs to complete the steps for the subsequent stage.
15. The computer-implemented method of claim 14 and further comprising:
if the subsequent stage corresponds to a different entity, then updating the entity display to show the different entity.
16. The computer-implemented method of claim 10 and further comprising:
displaying a process selection user interface display with process selection user input mechanisms that receive a selection user input selecting the selected process for performance.
17. The computer-implemented method of claim 16 wherein displaying the process selection user interface comprises:
identifying a user role; and
displaying process selection user inputs for only processes to which the user role has been granted access.
18. A computer readable storage medium storing computer executable instructions which, when executed by a computer, cause the computer to perform steps, comprising:
displaying a process identifying user interface display with identifying user input mechanisms that receive process identifying user inputs that identify a process to be configured, the identifying user input mechanisms including an entity identifier input mechanism that receives an entity identification user input identifying a first entity corresponding to the process;
displaying a process flow definition user interface display with process flow user input mechanisms that receive process flow user inputs that define a flow for the process, corresponding to the first entity, including an ordered set of stages for the first entity; and
after receiving the process identifying user inputs and the process flow user inputs, storing the process for access by users of the computer system.
19. The computer readable storage medium of claim 18 wherein the process comprises a business process in a business system and further comprising:
displaying a process selection user input mechanism; and
receiving a process selection user input, through the process selection user input mechanism, selecting the process for execution.
20. The computer readable storage medium of claim 19 and further comprising:
displaying a process user interface display, for the selected process, that includes a stages display showing an ordered set of stages that are to be performed, in order, to perform the selected process, and a steps display showing steps to be completed for a selected stage, along with steps user input mechanisms that receive steps user inputs to complete the steps;
displaying an entity display on the process user interface display that identifies an entity corresponding to the selected stage; and
displaying a location indicator, indicative of a location on the stages display that the selected process is in.